Viatris, Inc. (VTRS)
16.88
-0.06
(-0.35%)
USD |
NASDAQ |
Sep 04, 16:00
16.88
0.00 (0.00%)
After-Hours: 20:00
Viatris Research and Development Expense (Quarterly) : 245.20M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 245.20M |
| March 31, 2026 | 245.20M |
| December 31, 2025 | 259.80M |
| September 30, 2025 | 244.80M |
| June 30, 2025 | 216.00M |
| March 31, 2025 | 220.50M |
| December 31, 2024 | 205.40M |
| September 30, 2024 | 197.50M |
| June 30, 2024 | 204.10M |
| March 31, 2024 | 199.70M |
| December 31, 2023 | 199.80M |
| September 30, 2023 | 211.20M |
| June 30, 2023 | 208.30M |
| March 31, 2023 | 182.90M |
| December 31, 2022 | 181.00M |
| September 30, 2022 | 174.90M |
| June 30, 2022 | 162.60M |
| March 31, 2022 | 142.30M |
| December 31, 2021 | 254.30M |
| September 30, 2021 | 153.10M |
| June 30, 2021 | 143.80M |
| March 31, 2021 | 163.00M |
| December 31, 2020 | 153.30M |
| September 30, 2020 | 129.70M |
| June 30, 2020 | 156.10M |
| Date | Value |
|---|---|
| March 31, 2020 | 114.00M |
| December 31, 2019 | 151.80M |
| September 30, 2019 | 167.90M |
| June 30, 2019 | 147.60M |
| March 31, 2019 | 172.50M |
| December 31, 2018 | 148.20M |
| September 30, 2018 | 143.80M |
| June 30, 2018 | 194.90M |
| March 31, 2018 | 200.00M |
| December 31, 2017 | 202.40M |
| September 30, 2017 | 182.30M |
| June 30, 2017 | 181.10M |
| March 31, 2017 | 217.50M |
| December 31, 2016 | 194.60M |
| September 30, 2016 | 199.10M |
| June 30, 2016 | 179.50M |
| March 31, 2016 | 253.60M |
| December 31, 2015 | 159.00M |
| September 30, 2015 | 174.80M |
| June 30, 2015 | 168.20M |
| March 31, 2015 | 169.90M |
| December 31, 2014 | 150.20M |
| September 30, 2014 | 158.20M |
| June 30, 2014 | 155.40M |
| March 31, 2014 | 118.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 2.746B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Bristol Myers Squibb Co. | 2.316B |
| Johnson & Johnson | 3.603B |